Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

Abstract

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Müllerian tumor], and undifferentiated/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org.

The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study

“…Sentinel node mapping has been adopted and accepted worldwide for nodal evaluation in women with low-grade endometrial cancer [ 12 ]. However, a recent review of the literature conducted by How et al [ 22 ], they reported that SLN biopsy generated similar detection rates and accuracy as seen in low-grade disease.…”

“…In recent years, several publications have shown that SLN mapping is an effective method for identifying disease in the lymph nodes, reporting high sensitivity, low false-negative rates, as well as good negative predictive values [ 9 , 10 , 11 ]. The most recent National Comprehensive Cancer Network (NCCN) and ESGO guidelines [ 12 , 13 ] support SLN mapping as part of the surgical staging of endometrial cancer, providing there is strict adherence to the principles and algorithm of the technique [ 14 ]. The surgical SLN algorithm has been proposed to reduce the false-negative rare in women with disease apparently confined to the uterine body.…”

“…In the absence of SLN mapping on one or both sides, a side-specific lymphadenectomy should be performed, and any suspicious or enlarged node should be removed regardless of mapping [ 12 , 14 ]. Furthermore, surgeon expertise and attention to technical details are crucial.…”

Clinically Aggressive Uterine Epithelioid Leiomyosarcoma with Rhabdomyoblastic Differentiation and High Proliferation Rate: A Case Report

“…However, their clinical characteristics are not well known because the number of reported cases is too low. Generally, the treatment of choice of uterine leiomyosarcoma is total hysterectomy with or without bilateral salpingo-oophorectomy, and chemotherapy or external beam radiation therapy is optional [3]. In case of advanced stage, systemic chemotherapy can be considered, although postoperative treatment has not been established [4].…”

Construction of a mitochondria genes-based model for prognosis prediction, drug guidance and immune feature analysis in ovarian serous cystadenocarcinoma

“…It is now understood that the histological classi cation of EC cannot fully meet the clinical needs for predicting prognosis and guiding precise treatment due to the high heterogeneity of EC tissues and traditional histopathological diagnosis with low repeatability. The molecular classi cation ("TCGA classi cation") of EC was recently recommended by the National Comprehensive Cancer Network (NCCN) guidelines [21], which could assist prognosis evaluation, provide new strategies for individualized treatment, and bene t the prediction of immunotherapy. It has been established that HGOSC has an indolent response to platinum-and taxolbased chemotherapy [1].…”